Nasopharyngeal Carcinoma

220

Pipeline Programs↗

135

Active Trials↗

75

Companies Involved↗

Nasopharyngeal Carcinoma is a highly competitive landscape with 220 programs across 75 companies. The most active players are Argenx, AbbVie, CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.. 6 therapies are approved with 68 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

85/100

Pipeline Velocity

54/100

Mech. Concentration

10/100

Completion Rate

81/100

Attrition Rate

5/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

Argenx

1 program

AbbVie

1 program

CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

1 program

PersonGen BioTherapeutics (Suzhou) Co., Ltd.

1 program

GSK

1 program

Otsuka

1 program

Pipeline

Programs by Phase

Preclinical10

Pevonedistat

Takeda

Oxycodone

Protega

Tocilizumab

Roche

Asparaginase

Dutch Childhood Oncology Group

TPF+IMRT

Guiyang Medical University

Phase 122

Fludarabine

Sanofi

Fosaprepitant

Merck & Co.

Nab-Paclitaxel

Bristol-Myers Squibb

Valganciclovir

Engelhard Arzneimittel GmbH & Co.KG

Valproic Acid

AbbVie

Phase 2114

Pembrolizumab

Merck & Co.

Mitoxantrone Hydrochloride

Pfizer

Toripalimab

Coherus Oncology, Inc.

Sintilimab

Innovent Biologics (Suzhou) Co. Ltd.

Raltitrexed

Nanjing Chia-tai Tianqing Pharmaceutical

Phase 368

Cisplatin

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Cadonilimab

Shanghai Pharmaceuticals Holding Co., Ltd

Celecoxib

Philadelphia Eye Associates

Carboplatin

Avyxa

Nedaplatin

Jiangsu Simcere Pharmaceutical Co., Ltd.

Approved6

Gefitinib

AstraZeneca

Decitabine

Sun Pharma

Mitomycin

UroGen Pharma Ltd.

Irinotecan

Pfizer

Epirubicin

Pfizer

Analysis

Modality Breakdown

81%

Small molecule

219 of 270 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 270 classified programs, each share of the total. Modality classified for 100% of 283 pipeline programs.

Analysis

Trial Status

349

clinical trials

Unknown status119 · 34%

Completed77 · 22%

Recruiting72 · 21%

Not yet recruiting35 · 10%

Active, not recruiting27 · 8%

Terminated14 · 4%

Other5 · 1%

Clinical Trials

Trial Activity

349 trials

Intensified Treatments for Patients With Locally Advanced Nasopharyngeal Carcinoma With Detectable EBV DNA After One Cycle GP Regime Neoadjuvant Chemotherapy

Recruiting·FFudan University·Phase 3·NCT05772208·459 enrolled

KSD-101 Therapy for EBV-associated Nasopharyngeal Carcinoma: an Exploratory Clinical Trial

Recruiting·KKousai Bio Co., Ltd.·Phase 1·NCT06097793·12 enrolled

Reduced Volume of Neck Prophylactic Irradiation in Nasopharyngeal Carcinoma

Recruiting·SSun Yat-sen University·Phase 3·NCT05780372·474 enrolled

Toripalimab Vs. Placebo Wtih GP Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma

Recruiting·SSun Yat-sen University·Phase 3·NCT06712888·466 enrolled

TPC Versus GP Induction Chemotherapy for Nasopharyngeal Carcinoma

Recruiting·SSun Yat-sen University·Phase 2·NCT06301165·162 enrolled

Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma

Recruiting·SSun Yat-sen University·Phase 3·NCT04778956·218 enrolled

SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma

Recruiting·SSun Yat-sen University·Phase 2·NCT06323239·148 enrolled

Online Adaptive Radiotherapy for Nasopharyngeal Carcinoma

Recruiting·SSun Yat-sen University·Phase 3·NCT06516133·494 enrolled

Proton vs Photon IMRT in Locally Advanced Nasopharyngeal Carcinoma: A Phase III Trial

Recruiting·—·Phase 3·NCT07340515·300 enrolled

Nimotuzumab Combined With TGP as First-line Therapy in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

Recruiting·—·Phase 2·NCT06509009·30 enrolled

Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response

Recruiting·SSun Yat-sen University·Phase 3·NCT06239727·593 enrolled

Toripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal Carcinoma

Recruiting·SSun Yat-sen University·Phase 2·NCT07362979·243 enrolled

Sodium Bicarbonate for Reducing Radiation-Induced Oral Mucositis in Nasopharyngeal Carcinoma.

Recruiting·SSun Yat-sen University·Phase 2/3·NCT06854510·196 enrolled

18F-FDG PET/CT Guided Reduced-dose Radiotherapy for Nasopharyngeal Carcinoma

Recruiting·TTaizhou Hospital·Phase 2·NCT04813705·93 enrolled

GAPP Induction and Concurrent Chemoradiotherapy Followed by Toripalimab Maintenance for Nasopharyngeal Carcinoma.

Recruiting·SSun Yat-sen University·Phase 2·NCT06851247·47 enrolled

Page 1 of 24

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)